For research use only. Not for therapeutic Use.
TBI-223（Cat No.:I037029）is an investigational antibiotic targeting Mycobacterium tuberculosis, particularly effective against drug-resistant strains. It works by inhibiting the bacterial enzyme leucyl-tRNA synthetase, which is essential for protein synthesis and bacterial growth. In research, TBI-223 is valuable for studying tuberculosis treatment options, especially multidrug-resistant and extensively drug-resistant (XDR) TB cases. Its novel mechanism and specificity offer insights into overcoming TB resistance, making it a promising candidate in the development of next-generation TB therapies and expanding the arsenal against this challenging global health threat.
| Catalog Number | I037029 |
| CAS Number | 2071265-08-0 |
| Synonyms | TBI-223; TBI 223 |
| Molecular Formula | C17H20FN3O5 |
| Purity | 98% |
| Target | Bacterial |
| Solubility | Soluble in DMSO |
| Appearance | Solid powder |
| Storage | Store at -20°C |
| IUPAC Name | methyl N-[[(5S)-3-[3-fluoro-4-(2-oxa-6-azaspiro[3.3]heptan-6-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]carbamate |
| InChI | InChI=1S/C17H20FN3O5/c1-24-15(22)19-5-12-6-21(16(23)26-12)11-2-3-14(13(18)4-11)20-7-17(8-20)9-25-10-17/h2-4,12H,5-10H2,1H3,(H,19,22)/t12-/m0/s1 |
| InChIKey | ZNBRXLSWXJKKLJ-LBPRGKRZSA-N |
| SMILES | COC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CC4(C3)COC4)F |
| Reference | 1: Antibiotics in the clinical pipeline in October 2019 Mark S. Butler, David L. Paterson J Antibiot (Tokyo) 2020; 73(6): 329–364. Published online 2020 Mar 10. doi: 10.1038/s41429-020-0291-8 PMCID: PMC7223789 |
